Hiroshi Hongo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hiroshi Hongo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Takeo Kosaka
Department of Urology Keio University School of Medicine Tokyo Japan
3 shared publications - Mototsugu Oya
Department of Urology, Keio University Hospital, Tokyo 160-8582, Japan
2 shared publications Eriko Aimono
Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan
1 shared publication- Etsu Tashiro
Department of Biosciences and Informatics, Keio University, Kanagawa, Japan
1 shared publication - Himisha Beltran
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
1 shared publication - Hiroshi Nishihara
Center for Cancer Genomics, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 26 September 2024
- Published by Wiley in Cancer Science
- Vol. 115 (12) , 3997-4007
Selective killing of castration‐resistant prostate cancer cells by formycin A via the ATF4–CHOP axis
Prostate cancer is initially androgen‐dependent but often relapses to an androgen‐independent state called castration‐resistant prostate cancer (CRPC). Currently approved therapies have limited efficacy against CRPC, highlighting the need for novel therapeutic strategies. To address this need, we conducted a drug screen in our previously established aggressive CRPC cell model. We found that formycin A induced cell death in CRPC model cells but not in parental prostate cancer cells. In addition, formycin A upregulated death receptor 5 through the induction of endoplasmic reticulum stress, activating the “extrinsic” apoptosis pathway in CRPC model cells. Moreover, formycin A showed in vivo antitumor efficacy against CRPC xenografts in castrated nude mice. Thus, our findings highlight the potential of formycin A as a CRPC therapeutic.
- 26 September 2024
- Published by Wiley in Cancer Science
- Vol. 115 (12) , 3997-4007
Open AccessSelective killing of castration‐resistant prostate cancer cells by formycin A via the ATF4–CHOP axis
Prostate cancer is initially androgen‐dependent but often relapses to an androgen‐independent state called castration‐resistant prostate cancer (CRPC). Currently approved therapies have limited efficacy against CRPC, highlighting the need for novel therapeutic strategies. To address this need, we conducted a drug screen in our previously established aggressive CRPC cell model. We found that formycin A induced cell death in CRPC model cells but not in parental prostate cancer cells. In addition, formycin A upregulated death receptor 5 through the induction of endoplasmic reticulum stress, activating the “extrinsic” apoptosis pathway in CRPC model cells. Moreover, formycin A showed in vivo antitumor efficacy against CRPC xenografts in castrated nude mice. Thus, our findings highlight the potential of formycin A as a CRPC therapeutic.
- Open Access
- 21 December 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 3 (1) , pgae002
G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer
Although the treatment armamentarium for patients with metastatic prostate cancer has improved recently, treatment options after progression on cabazitaxel (CBZ) are limited. To identify the mechanisms underlying CBZ resistance and therapeutic targets, we performed single-cell RNA sequencing of circulating tumor cells (CTCs) from patients with CBZ-resistant prostate cancer. Cells were clustered based on gene expression profiles. In silico screening was used to nominate candidate drugs for overcoming CBZ resistance in castration-resistant prostate cancer. CTCs were divided into three to four clusters, reflecting intrapatient tumor heterogeneity in refractory prostate cancer. Pathway analysis revealed that clusters in two cases showed up-regulation of the oxytocin (OXT) receptor–signaling pathway. Spatial gene expression analysis of CBZ-resistant prostate cancer tissues confirmed the heterogeneous expression of OXT-signaling molecules. Cloperastine (CLO) had significant antitumor activity against CBZ-resistant prostate cancer cells. Mass spectrometric phosphoproteome analysis revealed the suppression of OXT signaling specific to CBZ-resistant models. These results support the potential of CLO as a candidate drug for overcoming CBZ-resistant prostate cancer via the inhibition of OXT signaling.
- 21 December 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 3 (1) , pgae002
Open AccessG-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer
Although the treatment armamentarium for patients with metastatic prostate cancer has improved recently, treatment options after progression on cabazitaxel (CBZ) are limited. To identify the mechanisms underlying CBZ resistance and therapeutic targets, we performed single-cell RNA sequencing of circulating tumor cells (CTCs) from patients with CBZ-resistant prostate cancer. Cells were clustered based on gene expression profiles. In silico screening was used to nominate candidate drugs for overcoming CBZ resistance in castration-resistant prostate cancer. CTCs were divided into three to four clusters, reflecting intrapatient tumor heterogeneity in refractory prostate cancer. Pathway analysis revealed that clusters in two cases showed up-regulation of the oxytocin (OXT) receptor–signaling pathway. Spatial gene expression analysis of CBZ-resistant prostate cancer tissues confirmed the heterogeneous expression of OXT-signaling molecules. Cloperastine (CLO) had significant antitumor activity against CBZ-resistant prostate cancer cells. Mass spectrometric phosphoproteome analysis revealed the suppression of OXT signaling specific to CBZ-resistant models. These results support the potential of CLO as a candidate drug for overcoming CBZ-resistant prostate cancer via the inhibition of OXT signaling.
- 1 October 2019
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 17 (5) , e897-e902
Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy
- 1 October 2019
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 17 (5) , e897-e902
Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy
- Open Access
- 10 February 2014
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 8 (1-2) , 86-8
Mucosa-associated lymphoid tissue lymphoma arising from the kidney
Primary renal lymphoma is rare, and most are intermediate- and high-grade lymphomas of B-cell lineage, such as diffuse large B-cellor Burkitt lymphoma. We report a case of low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) arising from the kidney. Only a few cases of primary renal MALT lymphoma have been published.
- 10 February 2014
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 8 (1-2) , 86-8
Open AccessMucosa-associated lymphoid tissue lymphoma arising from the kidney
Primary renal lymphoma is rare, and most are intermediate- and high-grade lymphomas of B-cell lineage, such as diffuse large B-cellor Burkitt lymphoma. We report a case of low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) arising from the kidney. Only a few cases of primary renal MALT lymphoma have been published.